Amgen disclosed ‘underwhelming’ rocatinlimab data, says Leerink

Leerink says Amgen disclosed “underwhelming” Phase 3 data for rocatinlimab in atopic dermatitis and Uplizna in myasthenia gravis in an investor call. Both therapies appear less efficacious than competing, approved products in their respective indications, the analyst tells investors in a research note. For rocatinlimab, the firm also highlights that Amgen did not disclose detailed safety data. It believes docatinlimab efficacy “appears weak” versus Dupixent while safety “is a question mark.” Amgen in early trading is down 4%, or $13.16, to $317.76. Leerink has a Market Perform rating on the name.